Siren, L.L.C. Denali Therapeutics Inc. Transaction History
Siren, L.L.C.
- $1.93 Trillion
- Q2 2025
A detailed history of Siren, L.L.C. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Siren, L.L.C. holds 821,513 shares of DNLI stock, worth $10.9 Million. This represents 0.59% of its overall portfolio holdings.
Number of Shares
821,513
Previous 821,513
-0.0%
Holding current value
$10.9 Million
Previous $11.2 Billion
2.91%
% of portfolio
0.59%
Previous 0.63%
Shares
2 transactions
Others Institutions Holding DNLI
# of Institutions
244Shares Held
134MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$174 Million0.01% of portfolio
-
Baillie Gifford & CO12MShares$158 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$156 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$87 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$82.8 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $1.77B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...